Similar articles for PMID: 19721859

Year	Number of Results
2000	1
2002	2
2003	4
2005	5
2006	2
2007	7
2008	5
2009	6
2010	7
2011	2
2012	2
2013	3
2014	5
2015	5
2017	3
2018	3
2019	9
2020	2
2021	1
2022	1
2023	2
2024	1

1

Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.

Kim MK, Ko SH, Baek KH, Ahn YB, Yoon KH, Kang MI, Lee KW, Song KH. Kim MK, et al. Korean J Intern Med. 2009 Sep;24(3):227-32. doi: 10.3904/kjim.2009.24.3.227. Epub 2009 Aug 26. Korean J Intern Med. 2009. PMID: 19721859 Free PMC article.

2

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Pistrosch F, et al. Diabetes. 2005 Jul;54(7):2206-11. doi: 10.2337/diabetes.54.7.2206. Diabetes. 2005. PMID: 15983223 Clinical Trial.

3

Association between rosiglitazone use and decline in renal function in patients with type 2 diabetes mellitus.

Feldman L, Shani M, Efrati S, Beberashvili I, Baevsky T, Weissgarten J, Vinker S. Feldman L, et al. J Nephrol. 2010 May-Jun;23(3):350-6. J Nephrol. 2010. PMID: 20155725

4

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group. Lachin JM, et al. Clin J Am Soc Nephrol. 2011 May;6(5):1032-40. doi: 10.2215/CJN.09291010. Epub 2011 Mar 31. Clin J Am Soc Nephrol. 2011. PMID: 21454723 Free PMC article. Clinical Trial.

5

Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.

Pistrosch F, Passauer J, Herbrig K, Schwanebeck U, Gross P, Bornstein SR. Pistrosch F, et al. Horm Metab Res. 2012 Nov;44(12):914-8. doi: 10.1055/s-0032-1314836. Epub 2012 Jun 21. Horm Metab Res. 2012. PMID: 22723267 Clinical Trial.

6

Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.

Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, Ianculescu C, Dumitrascu V, Giju S, Gluhovschi C, Bob F, Ursoniu S, Gadalean F, Velciov S, Bozdog G, Marian R. Petrica L, et al. Wien Klin Wochenschr. 2009;121(23-24):765-75. doi: 10.1007/s00508-009-1279-3. Wien Klin Wochenschr. 2009. PMID: 20047115 Clinical Trial.

7

Comparative effectiveness of incident oral antidiabetic drugs on kidney function.

Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Ikizler TA, Griffin MR. Hung AM, et al. Kidney Int. 2012 Apr;81(7):698-706. doi: 10.1038/ki.2011.444. Epub 2012 Jan 18. Kidney Int. 2012. PMID: 22258320 Free PMC article.

8

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Bakris G, et al. J Hum Hypertens. 2003 Jan;17(1):7-12. doi: 10.1038/sj.jhh.1001444. J Hum Hypertens. 2003. PMID: 12571611 Clinical Trial.

9

Renal function markers and metformin eligibility.

Tavares Bello C, Castro Fonseca R, Sousa Santos F, Sequeira Duarte J, Azinheira J, Vasconcelos C. Tavares Bello C, et al. Minerva Endocrinol. 2018 Sep;43(3):246-252. doi: 10.23736/S0391-1977.17.02626-8. Epub 2017 May 31. Minerva Endocrinol. 2018. PMID: 28565889

10

Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.

Qian Y, Li S, Ye S, Chen Y, Zhai Z, Chen K, Yang G. Qian Y, et al. J Endocrinol Invest. 2008 Dec;31(12):1069-74. doi: 10.1007/BF03345654. J Endocrinol Invest. 2008. PMID: 19246972

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year